CIK 0001341235 · Non-accelerated filer<br>Smaller reporting company
Aldeyra Therapeutics, Inc.
Sign in to watch- Ticker
- ALDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 781-761-4904
- Business address
- 23 BRADFORD STREET, SUITE 1, CONCORD, MA, 01742
- Former names
- Aldexa Therapeutics, Inc., Neuron Systems Inc
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 40,000 shares at $2.75 ($110,000)
- 4/A Grant or award Chief Financial Officer acquired 137,707 shares (grant or award)
- 4/A Grant or award Chief Commercial Officer acquired 247,480 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 250,000 shares (grant or award)
- 4 Grant or award Chief Commercial Officer acquired 250,000 shares (grant or award)
- 4 Grant or award President and CEO acquired 250,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy President and CEO bought 20,000 shares at $5.10 ($101,908)
- 4 Open-market buy President and CEO bought 8,710 shares at $5.68 ($49,483)
- 4 Open-market buy President and CEO bought 8,680 shares at $5.81 ($50,433)
- 4 Open-market buy President and CEO bought 14,288 shares at $5.91 ($84,465)
- 4 Open-market buy Director bought 1,700 shares at $5.85 ($9,945)
- 4/A Open-market buy President and CEO bought 21,547 shares at an average $5.91 ($127,449)
- 4 Open-market buy Director bought 5,000 shares at $6.00 ($30,000)
- 4 Open-market buy President and CEO bought 13,000 shares at an average $5.85 ($75,990)
- 4 Open-market buy Director bought 1,700 shares at $5.86 ($9,964)
Page 6 of 12 · 223 filings